Policy Developments - Jiangxi Province is promoting the development of brain-computer interface medical devices, emphasizing the need for regulatory compliance and collaboration among industry players to seize opportunities in emerging technologies [1] - The market for brain-computer interface medical devices is noted to have significant potential, with a strong development momentum in Jiangxi Province [1] Medical Device Approvals - In October, the National Medical Products Administration approved 204 medical device products, including 173 domestic Class III devices, 10 imported Class III devices, and 21 imported Class II devices [2] Pharmaceutical Logistics - The Shanghai Municipal Drug Administration encourages the development of modern pharmaceutical logistics, advocating for improved storage and management systems to enhance operational efficiency and reduce costs [3] Drug Approvals - Fangsheng Pharmaceutical announced that its Indobufen tablets received a drug registration certificate from the National Medical Products Administration, allowing for production [4] - Saito Bio's application for the chemical raw material drug Mometasone Furoate has been approved, indicating its use in treating asthma and skin conditions [5] - Tianyao Pharmaceutical received a drug registration certificate for Metoclopramide injection, which is used for treating nausea and vomiting [6] Capital Market Activities - Yingsi Intelligent submitted a listing application to the Hong Kong Stock Exchange, aiming to raise funds for its AI-driven drug development initiatives [7][8] - Rejuve Bio plans to repurchase shares worth between 100 million and 200 million yuan to support employee stock ownership plans [9] Industry Developments - AstraZeneca's Baxdrostat demonstrated significant reductions in 24-hour average systolic blood pressure in treatment-resistant hypertension patients during the Bax24 Phase III trial, achieving a reduction of 14.0 mmHg compared to placebo [10][11] - The drug showed good overall tolerability and consistent safety profiles, with a notable percentage of patients achieving target blood pressure levels [11] - Maiwei Bio's IL-11 monoclonal antibody 9MW3811 received approval for Phase II clinical trials targeting pathological scars, marking it as the first IL-11 targeted drug to enter clinical trials for this indication [12] - Aiwei Technology's subsidiary obtained a medical institution practice license, enabling it to provide third-party medical testing services [13] - Anke Bio signed an exclusive agency framework agreement with Boshengji for the PA3-17 injection product, aimed at enhancing its product portfolio in the innovative drug market [14][15]

证券代码：600488 证券简称：津药药业 编号：2025-066 津药药业股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 ■ 二、其他相关情况 盐酸甲氧氯普胺注射液作为镇吐药，主要用于化疗、放疗、手术、颅脑损伤、脑外伤后遗症、海空作业 以及药物引起的呕吐；用于急性胃肠炎、胆道胰腺、尿毒症等各种疾患之恶心、呕吐症状的对症治疗； 用于诊断性十二指肠插管前用，有助于顺利插管；胃肠钡剂X线检查，可减轻恶心、呕吐反应，促进钡 剂通过。2023年12月湖北津药向国家药品监督管理局药品审评中心提交该药品境内生产药品注册上市许 可申请并获受理，于2025年11月取得国家药品监督管理局颁发的药品注册证书。2024年2月公司子公司 津药和平（天津）制药有限公司盐酸甲氧氯普胺注射液通过仿制药质量和疗效一致性评价（详见公司公 告2024-005#）。截至目前，湖北津药在盐酸甲氧氯普胺注射液项目上已累计研发投入约590万元。 三、同类药品市场情况 近日，津药药业股份有限公司（以下简称"公司"）子公 ...

Core Viewpoint - The company, Tianyao Pharmaceutical (600488.SH), announced that its subsidiary, Hubei Tianyao Pharmaceutical Co., Ltd., has received the drug registration certificate for Metoclopramide Hydrochloride Injection from the National Medical Products Administration [1] Group 1 - The approved drug, Metoclopramide Hydrochloride Injection, is primarily used as an antiemetic for various conditions including chemotherapy, radiotherapy, surgery, and brain injuries [1] - The medication is indicated for symptomatic treatment of nausea and vomiting associated with acute gastroenteritis, biliary and pancreatic disorders, and uremia [1] - It also aids in facilitating duodenal intubation prior to diagnostic procedures and helps reduce nausea and vomiting during gastrointestinal barium X-ray examinations [1]

Core Viewpoint - Tianyao Pharmaceutical (600488) announced that its subsidiary, Hubei Tianyao Pharmaceutical Co., Ltd., received the drug registration certificate for Metoclopramide Hydrochloride Injection from the National Medical Products Administration, indicating a significant regulatory approval for a key product in its portfolio [1] Company Summary - Tianyao Pharmaceutical's subsidiary has been granted approval for Metoclopramide Hydrochloride Injection, which is primarily used as an antiemetic [1] - The injection is indicated for various conditions including chemotherapy, radiotherapy, surgery, and other medical situations that may cause nausea and vomiting [1] - The product also aids in diagnostic procedures such as duodenal intubation and enhances the passage of barium during gastrointestinal X-ray examinations [1] Industry Summary - The approval of Metoclopramide Hydrochloride Injection highlights the ongoing demand for antiemetic medications in the healthcare sector, particularly in oncology and gastroenterology [1] - This development may enhance the competitive positioning of Tianyao Pharmaceutical within the pharmaceutical industry, especially in the antiemetic market segment [1]

Core Viewpoint - The company announced that its subsidiary, Hubei Jinyao Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the registration certificate of Methoclopramide Hydrochloride Injection, which is expected to positively impact the company's performance and market expansion in the domestic formulation sector [1] Group 1 - The approved drug is classified as a Class 3 chemical drug and has passed the consistency evaluation of quality and efficacy for generic drugs [1] - The approval enhances the company's formulation product portfolio, which is anticipated to contribute positively to the company's performance [1] - The development, production, and sales of pharmaceuticals are subject to significant uncertainties due to national policies and market conditions [1]

Core Viewpoint - The company, Tianyao Pharmaceutical (600488.SH), announced that its subsidiary, Hubei Tianyao Pharmaceutical Co., Ltd., has received the drug registration certificate for Metoclopramide Hydrochloride Injection from the National Medical Products Administration [1] Group 1: Product Information - Metoclopramide Hydrochloride Injection is an antiemetic drug primarily used for nausea and vomiting caused by chemotherapy, radiotherapy, surgery, and other medical conditions [1] - The drug is also indicated for symptomatic treatment of nausea and vomiting associated with acute gastroenteritis, biliary and pancreatic disorders, and uremia [1] - Additionally, it aids in facilitating duodenal intubation and reduces nausea and vomiting during gastrointestinal barium X-ray examinations [1]

Core Viewpoint - The company has received approval for the drug Methochlorpromazine Hydrochloride Injection, which is primarily used as an antiemetic for various medical conditions [1] Group 1: Product Approval - The subsidiary Hubei Jinyao Pharmaceutical Co., Ltd. has obtained the Drug Registration Certificate from the National Medical Products Administration for Methochlorpromazine Hydrochloride Injection [1] - This injection is indicated for use in chemotherapy, radiotherapy, surgery, and conditions such as brain injuries and drug-induced vomiting [1] Group 2: Medical Applications - Methochlorpromazine Hydrochloride Injection is used for symptomatic treatment of nausea and vomiting associated with acute gastroenteritis, biliary and pancreatic diseases, and uremia [1] - It aids in diagnostic procedures such as duodenal intubation and reduces nausea during gastrointestinal barium X-ray examinations [1]

Core Viewpoint - Tianjin Pharmaceutical Industry (津药药业) announced that its subsidiaries, Tianjin Peace Pharmaceutical Co., Ltd. and Hubei Tian Pharmaceutical Co., Ltd., participated in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with seven products expected to be selected for this procurement [1] Group 1 - The subsidiaries involved in the procurement are Tianjin Peace Pharmaceutical and Hubei Tian Pharmaceutical [1] - The seven products proposed for selection include Betamethasone Sodium Phosphate Injection, Ambroxol Hydrochloride Injection, Metoclopramide Hydrochloride Injection, Theophylline Injection, Isoniazid Injection, Adrenaline Hydrochloride Injection, and Famotidine Injection [1]

Core Viewpoint - The company announced that its subsidiaries participated in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with seven products expected to be selected for this procurement [1] Group 1: Procurement Participation - The subsidiaries of the company, Tianjin Pharmaceutical Peace Pharmaceutical Co., Ltd. and Hubei Tianjin Pharmaceutical Co., Ltd., are involved in the national centralized drug procurement [1] - The seven products proposed for selection include Betamethasone Sodium Phosphate Injection, Ambroxol Hydrochloride Injection, Metoclopramide Hydrochloride Injection, Theophylline Injection, Isoniazid Injection, Adrenaline Hydrochloride Injection, and Famotidine Injection [1] Group 2: Financial Impact - The total projected sales revenue from the selected products for the year 2024 is approximately 95.16 million yuan, accounting for 2.96% of the company's total revenue for that year [1] - For the first three quarters of 2025, the projected sales revenue from these products is approximately 22.08 million yuan, representing 0.99% of the company's revenue for that period [1]

Group 1 - The company, China Resources Double Crane, announced the receipt of the drug supplement approval notice for Metoclopramide Hydrochloride Injection from the National Medical Products Administration [2] - The company also received the drug registration certificate for Lidocaine and Prilocaine Cream [2]